Evalve was incorporated in 1999 to design, develop, manufacture and market innovative devices to enable percutaneous repair of cardiac valves. The company’s initial products are intended to reduce the risks, trauma and costs associated with current open, arrested heart surgical options. The company’s present development and clinical efforts are focused on mitral valve repair.
An estimated 4 million people in the United States have significant mitral valve insufficiency, with an annual incidence of 250,000. Approximately 50,000 of these patients undergo surgery each year. Valve insufficiency, if left untreated, is associated with chronic volume overload, which ultimately leads to atrial fibrillation, heart muscle dysfunction, symptoms of congestive heart failure (CHF) and an increased risk of sudden death.
Financials
| Date | Type | Amount | Investors | Valuation |
|---|---|---|---|---|
| 11/27/07 | Series D | 60M | HowZat Media, Oxford University, Inventages, Whitefish Group, Highland Capital Partners, Greylock, Omidyar Network, SVB Financial Group, Neo Carta, Pharos, Centerpoint, Hicks, Muse, Tate & Furst Incorporated, Q Ventures | Unknown |